Zydus, an Indian pharmaceutical company, today launched its world's first novel drug 'Lipaglyn', used in treating Diabetic Dyslipidemia. The drug has already been approved by the Drug Controller General of India (DCGI)
"Lipaglyn provides patients suffering from diabetic dyslipidemia the option of a once-daily oral therapy, that has a beneficial effect on both lipid parameters as well as glycemic control," said Mr Pankaj R Patel, chairman and managing director, Zydus Cadila.
Diabetic Dyslipidemia is a health condition where the patient is a diabetic with high levels of total cholesterol, bad low-density lipoprotein (LDL) cholesterol and triglycerides, and a decrease in the good high-density lipoprotein (HDL) cholesterol concentrations in the blood.
Mr Paterl further added, "It has always been our dream to take a molecule right from the concept stage up to its launch. Today, we have realized this dream. It is an important breakthrough and I would like to dedicate this to all the Indian research scientists in the field of drug discovery."